STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #198 by analyst upside · 2026-06-27
APVO
Aptevo Therapeutics Inc.
Healthcare · Market Cap $6M · P/E 0.0x
ANALYST PRICE TARGET
+460.4%
implied upside to consensus target
Current Price $4.55
Consensus Target $25.5
Bull Target $30.0
Bear Target $21.0
Analysts Covering 2
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $3.8
52-Week High $59.4
YTD Return -51.5%
FUNDAMENTALS
Market Cap $6M
P/E Ratio (TTM) N/A
Forward P/E -0.2x
EPS (TTM) $1478.38
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.8
52-Week High $59.4
Current Price $4.55
Bear Target $21.0
Bull Target $30.0
● Now $4.55 ● Target $25.5
TRADING DATA
Avg Volume 37K
YTD Return -51.5%
Analyst Count 2
Consensus Buy
Upside to Target +460.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Aptevo Therapeutics Inc. (APVO) is currently trading at $4.55 with a Wall Street consensus price target of $25.5, implying potential upside of 460.4% over the next 12 months. 2 analysts currently cover APVO, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $21.0.

APVO operates in the Healthcare sector with a market capitalisation of $6M. The stock is down 51.5% year-to-date and is currently trading near the lower end of its 52-week range of $3.8 – $59.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →